Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$0.14 - $0.23 $42,270 - $69,444
301,931 Added 121.65%
550,131 $102,000
Q1 2022

May 13, 2022

BUY
$0.22 - $0.47 $41,272 - $88,172
187,600 Added 309.57%
248,200 $55,000
Q4 2021

Feb 11, 2022

BUY
$0.41 - $0.91 $20,582 - $45,682
50,200 Added 482.69%
60,600 $25,000
Q3 2021

Nov 12, 2021

SELL
$0.8 - $1.12 $291,028 - $407,439
-363,785 Reduced 97.22%
10,400 $10,000
Q2 2021

Aug 13, 2021

BUY
$0.97 - $1.32 $362,959 - $493,924
374,185 New
374,185 $427,000
Q3 2020

Nov 13, 2020

SELL
$1.71 - $2.51 $246,682 - $362,090
-144,259 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$1.77 - $4.23 $49,202 - $117,585
27,798 Added 23.87%
144,259 $320,000
Q1 2020

May 14, 2020

SELL
$1.64 - $3.85 $23,452 - $55,055
-14,300 Reduced 10.94%
116,461 $277,000
Q4 2019

Feb 13, 2020

SELL
$1.35 - $2.95 $34,574 - $75,552
-25,611 Reduced 16.38%
130,761 $384,000
Q3 2019

Nov 13, 2019

BUY
$1.5 - $2.99 $20,200 - $40,266
13,467 Added 9.42%
156,372 $235,000
Q2 2019

Aug 12, 2019

BUY
$1.93 - $2.95 $153,014 - $233,881
79,282 Added 124.61%
142,905 $400,000
Q1 2019

May 14, 2019

BUY
$1.35 - $2.68 $85,891 - $170,509
63,623 New
63,623 $131,000

About SOLENO THERAPEUTICS INC


  • Ticker SLNO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,101,250
  • Market Cap $362M
  • Description
  • Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing P...
More about SLNO
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.